T wo years ago several members of the British Thoracic Society independently suggested that, in the light of recent publications, the Standards of Care Committee should update their 1997 advice on suspected acute pulmonary embolism (PE). This issue of Thorax contains the results of this endeavour, with evidence sufficiently robust now to allow these to be called guidelines (see pp 470-83). Those familiar with the previous publication, to which the new document frequently refers, will recognise that the same basic structure has been used.
Previously, the main recommended option in the face of a non-diagnostic ventilation-perfusion (V/Q) scan was pulmonary angiography, an invasive test that was little used before and probably little more after. This advice has been made redundant by developments in CT pulmonary angiography (CTPA), with strong evidence that, even though a negative result may not entirely exclude PE, it does make anticoagulation unnecessary. There is no doubt that CTPA should now be considered the central imaging investigation in suspected PE, and many acute hospitals are developing experience of the techniques.
However, this adds a considerable workload to radiology departments already struggling to cope with the increased imaging requirements for cancer staging, not helped by the fact that PE is confirmed in only 20-35% of those where it has been suspected. This has led to different strategies for reducing the number of unnecessary CTPAs, but these too have their problems.
Some hospitals continue to use V/Q scanning as a way of obtaining a definite answer, but 30-50% of such patients will require CTPA anyway, which delays definitive investigations and lengthens hospital stay, and others do not have nuclear medicine on site. Indeed, were CTPA easily and rapidly available, V/Q scanning would become largely obsolete.
"There is no doubt that CTPA should now be considered the central imaging investigation in suspected PE"
Another approach is to restrict CTPA to patients who do not have the combination of low clinical probability and a negative D-dimer test. Since this halves the number requiring lung imaging it is an attractive option, but practical experience shows that there are pitfalls. Firstly, although the 1997 clinical probability assessment system has been retained (now on good evidence), the fact that it is very simple does not mean that junior doctors use it properly, as many senior clinicians and radiologists have discovered. Secondly, the seductive simplicity and low cost of D-dimer assays mean that, in many emergency departments, the test is done on a high proportion of patients who arrive with chest pain and/or breathlessness, even when another diagnosis is obvious, similar to the way that cardiac enzymes are often misused. The end result is that, where the D-dimer test happens to be positive, it is assumed that this makes PE more likely after all.
For these guidelines to work in practice without widespread abuse of the recommendations, the following policies should be introduced: (1) Clinical probability must be recorded in the admission notes and be included on every request form for CTPA, a policy that would be fruitful to audit regularly. (2) D-dimer tests may only be requested by junior doctors with at least 6 months post-registration experience of acute medicine. They should not be performed when CTPA is required anyway. (3) Request forms for CTPA which do not state clinical probability and (where appropriate) D-dimer results are automatically rejected by the radiology department, accompanied by a strong telephone message. (4) Where V/Q scanning remains part of the hospital's management algorithm, there should be a system in place whereby an inconclusive result leads to an automatic CTPA on the same day, without a further request having to be generated by the clinician.
(5) There should be at least one interested physician and radiologist who together review and refine both the hospital's policy and its application in practice.
These principles might appear draconian and unenforceable, yet several hospitals have been adopting them successfully for some time, finding that they stimulate good clinical thinking, reduce the number of unnecessary imaging tests, speed up the process of reaching a correct diagnosis, and are educationally valuable. Indeed, with the widespread changeover from unfractionated to low molecular weight heparin, an increasing number of patients are being quickly investigated and, where necessary, managed without being hospitalised.
Although the document is aimed primarily at junior physicians in UK Accident & Emergency departments, almost all the underpinning evidence comes from continental Europe and North America. Allowing for variations in resources, organisation and clinical practice in different countries and debates around interpretation of current data, it broadly reflects current international thinking and should prove useful elsewhere. Updated guidelines on the management of suspected acute pulmonary embolism are published in this issue of Thorax. CT pulmonary angiography has become the central imaging investigation in the diagnosis of pulmonary embolism, but it is important that its use is carefully controlled to avoid unnecessary investigations in overworked radiology departments.
M ost smokers become nicotine dependent and, when they stop smoking, experience withdrawal symptoms and craving. Nicotine replacement therapy (NRT) reduces these unpleasant symptoms and, theoretically, should decrease the risk of relapse. Smoking cessation is properly defined as validated sustained abstinence from cigarettes and/or other tobacco products for at least 6 months, but preferably for 1 year. This editorial includes evidence only from those studies which have applied such a definition and which have specified their settings and populations.
NRT is available as chewing gum, transdermal patches, sublingual tablets, lozenges, inhalation cartridges and nasal spray. In specialised cessation clinics [1] [2] [3] [4] [5] [6] [7] [8] and in primary care, 9 10 prospective randomised clinical trials have shown that NRT, used as an adjunct to advice and support, results in better cessation rates than does advice and support alone. In the clinics success rates with NRT tend to be higher (11-30%) and more consistent than in primary care, where some studies have found no significant difference from placebo. [11] [12] [13] [14] One study in primary care showed 8% success with nicotine chewing gum compared with 4% with advice plus leaflet, but there was no placebo controlled arm. 15 Two studies of transdermal nicotine in primary care have shown success rates of around 10%, which were superior to those with placebo (around 6%). 9 10 The benefit for transdermal nicotine in cessation clinics [6] [7] [8] and in primary care 9 10 is thus clear, whereas nicotine chewing gum, [1] [2] [3] [4] [5] inhaler, 16 17 nasal spray, 4 18 19 and lozenges 20 have only proved superior to placebo in cessation clinics. Success rates of 15-28% have been reported with nicotine inhaler compared with 5-18% with placebo, 16 17 21 the differences being significant in the first two studies but not in the third. Success rates with the nasal spray were higher than placebo in three studies (27% compared with 10-15%) 4 18 19 but not in a fourth. 22 Sublingual tablets were more effective than placebo at 6 months but not at 12 months in 247 smokers attending a department of oral and maxillofacial surgery. 23 Combinations of NRT have not usually done better than single versions, 21 24-26 but Blondal et al showed that prolonged treatment with nicotine patches (5 months) and nasal spray (12 months) produced better results than nicotine patches alone. 27 In a comparison of dosages, the large European CEASE trial reported a greater effect with a 25 mg patch (15.4% success) than with 15 mg (13.7% success, p<0.03), 8 but in the USA Jorenby et al 28 found that a 44 mg patch did no better than 22 mg. The 24 hour patch and the 16 hour patch produced similar quit rates 29 ; using the patch for 22 weeks rather than 8 weeks did not significantly improve the success rate. 8 In highly dependent smokers nicotine gum in a dosage of 4 mg was better than 2 mg
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; 5-20% of smokers can become addicted to nicotine gum. 31 32 This appears to be less of a problem with transdermal nicotine 33 and more of a problem with nasal spray. 4 Unwanted effects have tended to result from local irritation but occasionally-usually in those who continue to smoke while on NRT-systemic effects of excessive nicotine can occur (chiefly nausea). 16-18 20 22 23 26 27 In pregnancy and in patients with myocardial infarction NRT, which delivers less nicotine than cigarettes and no carbon monoxide, is less hazardous than continued smoking but, nevertheless, there is still reluctance to use it.
NRT is now available in the UK on NHS prescription. Smoking cessation counsellors have been employed by the NHS to provide advice and support in the community to smokers who self-refer or are referred by other health professionals. NRT is usually offered as part of the package. The sustained validated 6 month or 1 year quit rates achieved through this service are eagerly awaited. These results should not only inform local health groups, primary care trusts, and government of how cost effective the service has proved and how best to shape it in future, but should also make an interesting comparison with the results obtained in the clinical trials. For hospital inpatients and outpatients the evidence for the efficacy of NRT as an adjunct to advice and support is not convincing. Many reports stemming from cessation services located in hospitals have been wholly or partly based on populations of self-referred smokers or smokers recruited via the media. Such populations differ in motivation and other aspects from patients who, despite presenting to secondary care services, continue to smoke. Their quit rate should not therefore be taken as representing the quit rates of populations of patients. The first randomised trial of NRT in hospital patients in the UK enrolled 1550 inpatients or outpatients with smoking related diseases (SRDs); neither nicotine chewing gum nor its placebo significantly improved on the success rate of 9% achieved by brief advice from the hospital physician and follow up in an outpatient clinic at 3, 6 and 12 months. 34 This success rate is little different from the 11% reported from Nottingham by Molyneux et al 35 in this issue of Thorax in a study of hospital inpatients which was not restricted just to those with SRDs. Interventions compared were: (a) usual care, (b) 20 minutes' bedside counselling by a research doctor or nurse trained in smoking cessation counselling plus an advice leaflet, and (c) 20 minutes' bedside counselling by the same personnel plus 6 weeks of NRT. Patients were allowed to choose one of five forms of NRT, 63% electing transdermal nicotine. They were reviewed in outpatients or interviewed by telephone 3 and 12 months after entering the trial. Exhaled air carbon monoxide was used to validate claims of abstinence. In the usual care group 7.6% were classed as successes (continuous abstinence) compared with 4.4% in those receiving counselling plus advice leaflet and 11% in the counselling plus NRT group (p=0.25). Thus, like a previous trial by Campbell et al 36 of transdermal nicotine plus counselling in 234 hospital outpatients and inpatients with SRDs which showed 21% success with active versus 14% with placebo patches (p=0.15), there was a suggestion that NRT was of benefit but smaller than expected sample sizes have limited the power to detect differences caused by treatment rather than chance.
Previous trials of NRT and counselling in hospital patients with SRDs have included a group given NRT placebo, 34 36-38 a design feature missing in the Nottingham study. Nicotine chewing gum was no more effective (20% success) than placebo in a study of 219 inpatients, 37 nor was transdermal nicotine (14% success) better than placebo in 584 outpatients with ischaemic heart disease. 38 In a more recent outpatient 40 It is likely that UK hospitals will appoint smoking cessation counsellors to provide advice and support in conjunction with NRT or bupropion, as recommended by NICE. It is important not only that the success rates of these programmes be properly evaluated, but also that there should be further placebo controlled clinical trials of NRT in hospital patients. Such trials are both justified and desirable. A sthma is a disorder of the conducting airways in which Th2 mediated inflammation interacts with structural changes to cause variable airflow obstruction. Fundamental to disordered function is the concept of bronchial hyperresponsiveness (BHR) in which the airways constrict too much and too easily. In chronic severe asthma the inflammation and structural changes both become more intense 1 and are paralleled by an increase in BHR that is only partially or non-responsive to treatment with corticosteroids.
2 Explanations for BHR include mucosal and adventitial swelling causing a disproportionate reduction in airway calibre for a given degree of airways smooth muscle (ASM) shortening, 3 excessive ASM shortening, 4 an increase in ASM mass causing greater force generation, 5 and an excessive velocity of contraction linked to altered crossbridge cycling. 6 Morphometric studies have shown a graded increase in ASM mass in proportion to disease severity, and computer modelling has revealed that this and altered contractility are the most plausible explanations for BHR. 5 7 
IDENTIFICATION OF A NEW ASTHMA RELATED GENE
Asthma has a high heritability of up to 79%, 8 involving a few genes with moderate effects rather than many genes with small effects. 9 We have recently reported the first novel asthma related gene identified by positional cloning. 10 A genome wide screen was undertaken using phenotypic data and DNA from 362 families in Wessex and 98 in the USA with at least two siblings with asthma. Using 401 microsatellite markers at a density of 9 cM and multipoint linkage analysis, suggestive evidence for linkage (maximum lod score (MLS) 2.24) was found on the short arm of chromosome 20 at 9.99 cM. The addition of 13 more markers at 1-2 cM intervals increased the MLS to 2.94 at D20S482 (12.1 cM) which further increased to 3.93 when BHR was included in the definition of asthma (despite halving the sample size), thereby exceeding the threshold for genome wide significance. 11 In contrast, when asthma was conditioned for serum total IgE and allergen specific IgE as measures of the allergic component of asthma, the MLS fell to 2.3 at 11.6 cM and 1.87 at 12.1 cM. This indicated that the chromosomal region under the peak of linkage contained genes more closely linked to altered airway function than to measures of atopy. Confirmation for linkage on chromosome 20 has come from separate analysis of the UK and US families, 10 and from two separate genome wide studies in other UK and US outbred populations. 12 13 Physical mapping of the region under the peak of linkage on 20p13 and direct cDNA selection led to the identification of 40 genes. 10 Single strand conformational polymorphism (SSCP) analysis and direct sequencing was used to identify single nucleotide polymorphisms (SNPs) used for case-control association studies involving 130 affected individuals who contributed to the linkage signal on chromosome 20 and 217 controls with no personal or family history of either asthma or allergy-that is, "hypernormals". In 23 genes spanning the 90% confidence interval on each side of D20S482, 135 SNPs were typed of which 25 were localised to a cluster of five genes showing significant association with both asthma and BHR. Fourteen of these lay within a single gene identified as ADAM 33, a novel member of the ADAM (A Disintegrin And Metalloproteinase) family (achieving significance of p=0.005-0.05). Both in the combined populations and in the UK and US samples when analysed separately, additional SNP typing strengthened the location of the signal to ADAM 33 and this was further confirmed both by haplotype analysis (5-7 SNP combinations at p=0.000003-0.005) and transmission disequilibrium testing (TDT) (8 SNP combinations at p<0.005). The association of SNPs in ADAM 33 with asthma has recently been confirmed in three different ethnic populations in the USA, one in Holland, 14 and in separate casecontrol and family studies in Germany (M Wijst, personal communication).
CHARACTERISTICS OF THE ADAM GENE FAMILY
ADAM 33 is the most recently reported member of the ADAM gene family of Zn ++ dependent matrix metalloproteases (MMPs). ADAMs have a complex organisation involving eight domains, the first six encoding signal sequence and pro-, catalytic, disintegrin, cysteine rich and EGF domains 15 which are anchored at the cell surface or Golgi apparatus by a transmembrane domain, followed by a cytoplasmic domain with intracellular signalling specific sequences (fig 1) . ADAM 33 belongs to the ADAM 12, 15 and 19 subfamilies, all of which possess proteolytic activity. 15 16 Northern blot analysis identified two transcripts of ADAM 33 of 5.0 and 3.5 kb, but only the latter has been found in cytoplasmic RNA. 10 Seventeen cDNA libraries have been screened resulting in the identification of a 3.5 kb clone containing the entire open reading frame comprising 22 exons with the canonical sequence (CT/AG) present at each splice junction. The potential for alternatively spliced transcripts is also indicated by the identification of variants lacking exons, or parts of exons. ADAM 33 is preferentially expressed in smooth muscle, myofibroblasts and fibroblasts, but not in epithelial cells, T cells or inflammatory leukocytes. 10 17 The significance of ADAM 33 for asthma is strengthened by the existence of a syntenic region on mouse chromosome 2 at 74 cM that has been linked to BHR 18 overlying an orthologue of ADAM 33 that exhibits approximately 70% homology with its human counterpart. 17 19 The selective expression of ADAM 33 in mesenchymal cells strongly suggests that alterations in its activity may underlie abnormalities in the function of ASM cells and fibroblasts linked to BHR in asthma. These components of the epithelial-mesenchymal trophic unit (EMTU) 20 share a common fibroblastic progenitor, the mature phenotype of which is directed by growth factors, Asthma gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ADAM 33, the latest of the ADAM proteins to be described, has been identified as a major susceptibility gene in asthma linked to bronchial hyperresponsiveness. It provides an important breakthrough in our understanding of this complex disorder and its variable clinical and physiological presentations. 21 22 whose release from bronchial epithelial cells is increased in response to epithelial damage and airway inflammation. 23 24 Asthmatic (myo) fibroblast cells are unusual in that they have the capacity to proliferate in the absence of exogenous growth factors, 21 25 paralleling the behaviour of asthmatic ASM cells in vitro. 26 This shared trait is consistent with the occurrence of a common stem cell population whose numbers are increased in asthma due to an inherent capacity for enhanced growth and/or survival.
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Members of the ADAM family are proteins with diverse functions that reflect the complex domain structure of these molecules (fig 1) . 15 While certain functions can be attributed to an individual domain-for example, ectodomain shedding to the metalloproteinase domain 27 and cell adhesion to the disintegrin domain 28 -it is likely that the other domains play important regulatory roles in these functions by conferring specificity and selectivity. ADAM proteins are anchored in the trans-Golgi network or plasma membrane but, in some cases, secreted splice variants have been identified. In the case of ADAM 12, an evolutionarily close relative of ADAM 33, ectopic expression of the secreted form of the molecule (ADAM 12S) in rhabdomyosarcoma cells results in growth of tumour xenografts which are infiltrated with large numbers of host derived smooth muscle cells. 29 Although we have identified several alternatively spliced forms of ADAM 33 in lung derived cDNA, it is not yet known whether a secreted protein variant is produced by airway cells.
The importance of genetic variation in ADAM proteins has recently been highlighted by mutations in ADAMTS13 (ADAM with thrombospondin type 1 motif) that underlie thrombotic thrombocytopenic purpura, 30 while decreased levels of ADAMTS2 impair collagen type 1 processing leading to fragile skin in Ehlers-Danlos syndrome. 31 
POSSIBLE ROLE OF ADAM 33 IN ASTHMA AND BHR
Although ADAM 33 is a highly polymorphic gene containing over 55 SNPs, genetic analyses have identified the 3′ portion of the gene that encodes the transmembrane and cytoplasmic domains and 3′UTR as likely to be the key region linked to asthma and BHR. 10 In the UK population association studies revealed that six SNPs in the ADAM 33 gene were significant at p<0.03, including two (S 1 and S 2 ) in the exon encoding the transmembrane domain (p=0.03 and 0.004, respectively) and another (ST +4 ) which lies in the intron separating the transmembrane and cytoplasmic domains (p=0.02, fig 1) . When ST 2 and ST +4 were analysed as a haplotype or with SNPs in the intron preceding the V exon, the level of significance greatly increased (p=0.000003-0.0005). Further confirmation that the transmembrane and intracellular domains are key sites for controlling altered functions of ADAM 33 comes from TDT analyses in the UK population. In this case the exonic S 1 SNP, which leads to an amino acid substitution (V→1 (one letter code)), showed a significant association with asthma (p=0.0043) and BHR (p=0.0066). Additional haplotype analysis increased the significance of the association of this SNP with asthma and BHR when taken in conjunction with the T 1 , an SNP which causes an amino acid substitution (M→T) in the cytoplasmic domain, and with SNPs in the V exon encoding the end of the cytoplasmic domain and the 3′UTR (p=0.0001). Considering that the S 1 and T 1 SNPs occur in close proximity in the transmembrane and cytoplasmic domains of ADAM 33 and flank the intronic ST +4 SNP (fig 1) , polymorphisms in this region together with others in the 3′UTR may alter the activity of ADAM 33, conferring susceptibility to BHR and asthma. However, without further genetic and functional studies it is difficult to attribute primacy to any individual SNP because of the extent of linkage disequilibrium that exists in this region.
The cytoplasmic domains (CTD) of ADAM proteins are typically rich in proline and have important regulatory functions through their interaction with intracellular signalling proteins via SH2 and/or SH3 domains. Furthermore, the presence of alternatively spliced cytoplasmic variants of ADAM 22 have been shown to exhibit cell selective expression. Yeast two hybrid, western blotting, and pull down assays have identified several proteins that interact with the ADAMs, including src family kinases, endophilin, α-actinin, PACSIN, and protein kinase C (PKC). 27 32-35 Together with the transmembrane domain, the CTD mediates interactions with the cytoskeleton and is involved in intracellular trafficking of the protein. 36 For example, phosphorylation of ADAM 9 by PKC causes trafficking of the protein from the Golgi to the plasma membrane where it cleaves heparin binding EGF-like growth factor (HB-EGF) from its membrane bound precursor. 27 In the case of ADAM 33, the intracellular domain is relatively short by comparison with its nearest homologues but it is very rich in prolines and has a putative SH3 binding site (P s WPLDP) in which the T 2 SNP is located and may affect function. There is also a casein kinase F/II phosphorylation site (SHEPSSHP) and a MAPK consensus sequence which could be important regulators of ADAM 33 function. Although the T 1 SNP causes an M→T substitution, no new recognisable phosphorylation site is generated.
ADAM 33 is amply provided with a number of other mechanisms whereby its disordered function could translate into BHR although, at this time, it is not clear whether changes in ADAM 33 linked to asthma relate to a gain or loss in function. 37 38 In many ADAMs the proteolytic site has the capacity to release cytokines and growth factors from their precursors. For example, ADAM17 (TNFα converting enzyme (TACE)) is responsible for generating both TNFα and TGFα, 39 while ADAMs 9 and 12 cleave HB-EGF from its precursor. 27 28 In a mouse model of hypertension induced cardiac hypertrophy a pivotal role for myocardial ADAM 12 has been shown through its capacity to generate HB-EGF. 40 Loss of function may lead to impaired processing of cytokines and growth factors. Reduced processing of myostatin, a member of the TGF-β/ BMP superfamily, is associated with differentiation into myotubes. 41 Several of the ADAM family members are involved in cell-cell and cell-matrix interactions involving members of the integrin family, 42 although binding to syndecans, 43 members of the tetrapsanin family, and unknown proteins has also be shown.
Binding of fibroblasts to a soluble ADAM group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from 9:Fc fusion protein via α 6 β 1 causes a very large increase in cell motility, which suggests that the ADAM could act as a locomotor adhesion receptor. 44 In contrast, overexpression of ADAM 15 decreases cell migration by increasing cellcell contacts without affecting initial cell adhesion. 45 In conjunction with the cysteine rich domain, a novel secreted form of ADAM 12 provokes myoblast fusion in vivo by binding to the muscle specific actin binding protein, α-actinin-2.
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If the equivalent domain in ADAM 33 has similar properties, it could be implicated in converting ASM cells from acting as multiple units to a single contractile unit, 46 a property relevant to the pathogenesis of BHR.
CONCLUSIONS
The identification of ADAM 33 as a major susceptibility gene in asthma linked to BHR is an important breakthrough in our understanding of this complex disorder and its variable clinical and physiological presentations. 47 ADAM 33 is the latest of the ADAM proteins to be described, 17 19 with its implication in the pathogenesis of asthma being discovered in the same year. Identifying a major new candidate gene for asthma creates an imperative to determine its function and how disordered function translates into disease. The work ahead is likely to provide important insights into the origins and progression of asthma, especially since expression of ADAM 33 has now been shown in fetal lung tissue. It is not infrequently stated that searching the whole genome for susceptibility genes in complex diseases such as asthma is a fruitless "fishing expedition". However, as recently pointed out by Ahmadi and Goldstein, 47 a sequential approach to identifying novel genes in complex disorders by combining linkage and association approaches can achieve success without having to resort to expensive and time consuming genomewide association mapping. To achieve this in any complex disease it is becoming increasingly appreciated that it is essential to define the disease phenotype accurately. ADAM 33 can now be added to calpain 10 (type 2 diabetes) 48 and NOD 2 (Crohn's disease) 49 as an entirely novel molecule linked to the pathogenesis of a complex human disease. The future challenge will be to determine the function(s) of ADAM 33 and the abnormalities that may occur to account for its association with asthma and BHR. 
